{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:05:02Z","timestamp":1789430702149,"version":"build-2803163510"},"reference-count":41,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clinical Trials"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Aims:<\/jats:title>\n                    <jats:p>Global megatrends, including population growth, interconnectedness and artificial intelligence, are already shaping the clinical trials industry, and will do so for decades to come. Innovations from technology companies, greater collaboration with patients and caregivers, and increased diversity in clinical trials could transform clinical trials of the future. However, the industry has typically been slow to adopt new technologies, and certain barriers could stifle innovation and allow health inequalities to persist. Our aim was to explore the trends shaping clinical trials and identify initiatives that can be started now to move toward a future where patients are actively involved in clinical trial design and decision-making, and technologies like artificial intelligence are integrated responsibly and ethically into clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used strategic foresight methodology to explore the trends that will shape the future of clinical trials and how the trajectory of these trends could lead to different future scenarios We then identified initiatives that could help us move toward our desired scenario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified four possible scenarios for the future of clinical trials based on two key trends: data sharing and adaptation of regulatory frameworks. While the future will see collection of large amounts of data from different sources, such as databases and wearable devices, their usefulness could be limited if data remain in silos, limited by strict regulations and a lack of trust in data privacy. Alternatively, data may be integrated more efficiently into clinical trials if regulators adapt proactively to new technologies and patients are empowered to take control over their data, for example. We identified initiatives that can be started now to achieve our vision. Pharmaceutical companies, academic researchers, non-governmental organizations (including patient organizations), regulatory authorities, policymakers, technology companies and innovative service providers must join forces and work on initiatives to integrate technology into trials, enable data sharing, harmonize regulations across regions, co-design trials with patients and caregivers, strengthen decentralized trial capabilities and promote diversity in trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Through a collaborative cross-industry effort that prioritizes proactive patient involvement and responsible use of technology, we can shape a clinical trial ecosystem that is inclusive, ethical and ready for the future. We urge all stakeholders to act now on these initiatives to positively influence the future of clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17407745251414680","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:20:26Z","timestamp":1772104826000},"page":"309-319","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Shaping the future of clinical trials through strategic foresight"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5237-9230","authenticated-orcid":false,"given":"Sharon","family":"Lee","sequence":"first","affiliation":[{"name":"Canadian Pulmonary Fibrosis Foundation (CPFF), Toronto, ON, Canada"},{"name":"Patient Author"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Patient Author"},{"name":"Global Liver Institute, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Robertson","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Kallsen","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bauer","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Universit\u00e0 Politecnica delle Marche\u2014AOU Marche, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2517","authenticated-orcid":false,"given":"Christian","family":"Boisvert-Huneault","sequence":"additional","affiliation":[{"name":"Patient Author"},{"name":"Psoriasis Canada, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Clerisme-Beaty","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"UCL Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fakra","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital of St-Etienne, Saint-Priest-en-Jarez, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Geissler","sequence":"additional","affiliation":[{"name":"Patient Author"},{"name":"Patvocates, Riemerling, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[{"name":"University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Patient Author"},{"name":"One Step, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manya","family":"Lind","sequence":"additional","affiliation":[{"name":"Copenhagen Institute for Futures Studies, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Yale University\/Yale Cancer Center, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Perry","sequence":"additional","affiliation":[{"name":"Patient Author"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claas","family":"R\u00f6hl","sequence":"additional","affiliation":[{"name":"Patient Author"},{"name":"EUPATI Austria, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Francisco Kerr","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Pontifical Catholic University of Campinas, Campinas, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Swarup","sequence":"additional","affiliation":[{"name":"Patient Author"},{"name":"Crohn\u2019s &amp; Colitis Society of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Szpisjak","sequence":"additional","affiliation":[{"name":"Copenhagen Institute for Futures Studies, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Flyvbjerg","sequence":"additional","affiliation":[{"name":"J. E. Ohlsens Gade 4, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53211-z"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.71839"},{"key":"e_1_3_3_4_2","unstructured":"European Strategy and Policy Analysis System. Global trends to 2030. Challenges and choices for Europe. https:\/\/ec.europa.eu\/assets\/epsc\/pages\/espas\/ESPAS_Report2019.pdf (2019 accessed 11 April 2024)."},{"key":"e_1_3_3_5_2","unstructured":"Shoup TM. Global megatrends: shaping the future of societies economies and values. https:\/\/mailchi.mp\/cifs\/megatrends-report-download (2022 accessed 28 August 2024)."},{"key":"e_1_3_3_6_2","unstructured":"World Health Organization. Number of clinical trials by year country WHO region and income group (1999-2022) https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/number-of-clinical-trials-by-year-country-who-region-and-income-group (2023 accessed 28 August 2024)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4139-0"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2022.101742"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102243"},{"key":"e_1_3_3_10_2","unstructured":"National Academies of Sciences Engineering and Medicine. Improving representation in clinical trials and research: building research equity for women and underrepresented groups. Report National Academies Press Washington DC 2022."},{"key":"e_1_3_3_11_2","unstructured":"U.S. Food and Drug Administration. Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies guidance for industry. Draft guidance https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies (2024 accessed 28 August 2024)."},{"key":"e_1_3_3_12_2","unstructured":"European Parliament. Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use and repealing Directive 2001\/20\/EC Text with EEA relevance http:\/\/data.europa.eu\/eli\/reg\/2014\/536\/2022-12-05 (2022 accessed 28 August 2024)."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1476-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02160-z"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05489-x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2021-000087"},{"key":"e_1_3_3_17_2","unstructured":"IQVIA. A sponsor\u2019s perspective: why digital adoption lags in clinical trials https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/articles\/a-sponsors-perspective_why-digital-adoption-lags-in-clinical-trials-march-12.pdf (2025 accessed 6 June 2025)."},{"key":"e_1_3_3_18_2","unstructured":"Miller HI Henderson DR. The FDA\u2019s risky risk-aversion https:\/\/www.hoover.org\/research\/fdas-risky-risk-aversion (2007 accessed 6 June 2025)."},{"key":"e_1_3_3_19_2","article-title":"Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness","volume":"368","author":"Vollmer S","year":"2020","unstructured":"Vollmer S, Mateen BA, Bohner G, et al. Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness. BMJ 2020; 368: l6927.","journal-title":"BMJ"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/jme-2022-108696"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18168477"},{"key":"e_1_3_3_22_2","unstructured":"Voros J. A primer on futures studies foresight and the use of scenarios https:\/\/foresightinternational.com.au\/wp-content\/uploads\/2020\/03\/Voros-Primer-on-FS-2001-Final.pdf (2001 accessed 26 November 2024)."},{"key":"e_1_3_3_23_2","unstructured":"Stanford University. The Stanford emerging technology review 2025. Report Stanford University Stanford CA 2025."},{"key":"e_1_3_3_24_2","unstructured":"United Nations Department of Economic and Social Affairs. World population prospects 2024. Report United Nations New York 2024."},{"key":"e_1_3_3_25_2","unstructured":"United Nations Department of Economic and Social Affairs. UN DESA Policy Brief No. 140: a world of 8 billion. Report United Nations New York 2022."},{"key":"e_1_3_3_26_2","unstructured":"United Nations Department of Economic and Social Affairs. World population prospects 2022. Report United Nations New York 2022."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032884"},{"key":"e_1_3_3_28_2","unstructured":"Fengler W Kharas H Caballero J. Asia\u2019s tipping point in the consumer class https:\/\/www.brookings.edu\/articles\/asias-tipping-point-in-the-consumer-class\/ (2022 accessed 28 August 2024)."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000511889"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw055"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1629-x"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.167099"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12596"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afab282"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.2750"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2017.05.017"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/2168479015580384"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106219"},{"key":"e_1_3_3_39_2","unstructured":"United Nations. The sustainable development goals report. Report United Nations New York 2022."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn267"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"e_1_3_3_42_2","unstructured":"Government of Canada. What we heard: consultations on clinical trials regulatory modernization initiative (spring and summer 2021) https:\/\/www.canada.ca\/en\/health-canada\/programs\/consultation-clinical-trials-regulatory-modernization-initiative\/what-we-heard.html (2024 accessed 18 February 2025)."}],"container-title":["Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17407745251414680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17407745251414680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17407745251414680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:56:32Z","timestamp":1781006192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17407745251414680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/17407745251414680"],"URL":"https:\/\/doi.org\/10.1177\/17407745251414680","relation":{},"ISSN":["1740-7745","1740-7753"],"issn-type":[{"value":"1740-7745","type":"print"},{"value":"1740-7753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}